SCHEMBL720556

SCHEMBL720556

CC(C)c1cc2c(c(O)c1O)[C@@]1(CO)CCCC(C)(C)[C@@H]1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 15/20 1.00
▸ BCL9 O00512 3/20 0.64
▸ CTNNB1 P35222 3/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ CYP3A4 P08684 2/20 0.64
▸ MAPT P10636 2/20 0.64
▸ HPGD P15428 2/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ PTGES O14684 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ PNLIP P16233 1/20 0.64
▸ ALOX12 P18054 1/20 0.64
▸ GSTO1 P78417 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ KDM4E B2RXH2 1/20 0.64
▸ USP2 O75604 1/20 0.64
▸ TP53 P04637 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ HSD17B10 Q99714 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30525550 1.00 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
SCHEMBL6658577 0.89 FDPS (0.80) FDPSBCL9CTNNB1ALDH1A1CYP3A4
SCHEMBL32659910 0.83 FDPS (0.70) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Pisiferol SCHEMBL27950408 0.82 FDPS (0.70) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Pisiferol SCHEMBL30298475 0.82 FDPS (0.70) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL12590737 0.78 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL9923661 0.78 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL13309664 0.78 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL29390188 0.78 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL18290359 0.78 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2083809-B1 DIETARY OR PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES FOR THE TREATMENT OF DEPRESSION. DSM IP ASSETS BV (NL) 2014-05-07 — — EP claimed
US-8552055-B2 Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivates and their uses DSM IP ASSETS B.V. (NL) 2013-10-08 — — US claimed
US-20100099753-A1 Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivates and their uses DSM IP ASSETS B.V. (NL) 2010-04-22 — — US claimed
US-20100056615-A1 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS DSM IP ASSETS B.V. (NL) 2010-03-04 — — US claimed
US-20090099251-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2009-04-16 — — US claimed
EP-1925302-A1 Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression DSMIP Assets B.V. (NL) 2008-05-28 — — EP claimed
EP-1925301-A1 Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders DSMIP Assets B.V. (NL) 2008-05-28 — — EP claimed
EP-4114383-B1 TRICYCLIC DITERPENE ISOLATED FROM PINE ROSIN FOR THE TREATMENT OF PAIN AND INFLAMMATION UNIV SOUTH FLORIDA (US) 2023-08-09 — — EP disclosed
US-8748491-B2 Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivatives and their uses DSM IP ASSETS B.V. (NL) 2014-06-10 — — US disclosed
EP-2083809-B1 DIETARY OR PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES FOR THE TREATMENT OF DEPRESSION. DSM IP ASSETS BV (NL) 2014-05-07 — — EP disclosed
US-20140005270-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2014-01-02 — — US disclosed
JP-2013255495-A COMPOSITION COMPRISING CARNOSIC ACID 12-METHYLETHER DSM IP ASSETS BV 2013-12-26 — — JP disclosed
JP-2013227328-A USE OF TRICYCLIC DITERPENE AND THE DERIVATIVE FOR TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDER AND/OR JOINT DISORDER DSM IP ASSETS BV 2013-11-07 — — JP disclosed
US-20090099251-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2009-04-16 — — US disclosed
WO-2008061754-A1 DIETARY OR PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND DERIVATIVES THEREOF FOR THE TREATMENT OF DEPRESSION DSM IP ASSETS B.V. (NL) 2008-05-29 — — WO disclosed
WO-2008061720-A2 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS DSM IP ASSETS B.V. (NL) 2008-05-29 — — WO disclosed
EP-1925302-A1 Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression DSMIP Assets B.V. (NL) 2008-05-28 — — EP disclosed
EP-1925301-A1 Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders DSMIP Assets B.V. (NL) 2008-05-28 — — EP disclosed
EP-1925301-A1 Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders DSMIP Assets B.V. (NL) 2008-05-28 — — EP disclosed
EP-1925301-A1 Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders DSMIP Assets B.V. (NL) 2008-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099753-A1 Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivates and their uses CHRM1, CYP8B1, OXER1 FDPS 1255/4885BCL9 2901/4885CTNNB1 2674/4885
US-20090099251-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES CHRM1, CYP8B1, OXER1 FDPS 1222/4885BCL9 2989/4885CTNNB1 2588/4885
US-20140005270-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES CHRM1, CYP8B1, HCRTR1 FDPS 1192/4885BCL9 2950/4885CTNNB1 2741/4885
US-20100056615-A1 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS TNF, VDR, CYP24A1 FDPS 56/4885BCL9 2980/4885CTNNB1 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback